Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
Date:9/13/2012

SAN FRANCISCO, Sept. 13, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2012 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Wednesday, September 19, 2012 at 10:30 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until October 20, 2012.

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
2. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
3. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
6. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
7. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
8. Pearl Therapeutics Completes Phase 2b Study of Glycopyrrolate, Defines Dose-Response Curve and Identifies Optimal Dose of PT001
9. RNL BIO, a South Korean adult stem cell firm, introduces its autologous stem cell therapeutics in Turkey to treat patients with various intractable diseases
10. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
11. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... BETHESDA, Md. , March 2, 2015 ... on treating and preventing autoimmune diseases, announced today that ... (AMG 714) from Amgen (NASDAQ: AMGN ). ... has the rights to develop, manufacture and commercialize AMG ... . Concurrently, Amgen has been granted an exclusive ...
(Date:3/2/2015)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... for cells and tissues  ("BioLife" or the "Company"), ... Company its 2015 Silver Awardee for Achievement in Medical ... Michael Romoser described the environment for the awards ...
(Date:3/2/2015)... , Abbott Diabetes Care, American Association of ... Apple, Arkray, Asante Solutions, A. Menarini, Bayer ... Carewell Biotech, Centres for Medicare and Medicaid ... for Disease Control and Prevention (CDC), Carlyle ... Chugai, Conceptus, Covidien, Cygnus, ConvaTec, Constitution Medical ...
Breaking Medicine Technology:Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3BioLife Solutions Wins Washington State 2015 Silver Award for Achievement in Medical Technology from Seattle Business Magazine 2BioLife Solutions Wins Washington State 2015 Silver Award for Achievement in Medical Technology from Seattle Business Magazine 3Blood Glucose Meters Industry 2019 Forecasts for Global and Chinese Regions 2
... honored 12 outstanding PhD students and two professors with the ... in the field of organic chemistry. The winners are participating ... in Chemistry to gain first hand knowledge on the ... "These students come from a broad range of universities ...
... 2011 Echo Therapeutics, Inc. (OTCBB: ... as a non-invasive, wireless, transdermal continuous glucose monitoring ... transdermal drug delivery, announced that it has received ... tCGM System design.  This newly-engineered design is currently ...
Cached Medicine Technology:Roche Symposium Showcases Accomplishments of Next Generation of Chemists 2Echo Therapeutics Announces Symphony™ tCGM System Progress 2Echo Therapeutics Announces Symphony™ tCGM System Progress 3
(Date:3/2/2015)... 2015 The Workgroup for Electronic Data ... use of health IT to create efficiencies in healthcare ... for Small Providers.” The white paper by WEDI’s ICD-10 ... for ICD-10 testing by focusing on primary considerations and ... with the October 1, 2015 implementation date. Download the ...
(Date:3/2/2015)... 02, 2015 The minimally invasive ... a CAGR of 6.1% to reach $14,133.0 million ... , Factors such as advantages of minimally invasive ... owing to minimally invasive surgeries and increasing number ... driving the global minimally invasive surgical instruments market. ...
(Date:3/2/2015)... TX (PRWEB) March 02, 2015 ... lot easier thanks to the success of ... meal planning easy and delicious for thousands of ... positive customer feedback by expanding to offer a ... Tastes, which features seasonally appropriate classic recipes and ...
(Date:3/2/2015)... WI (PRWEB) March 02, 2015 ... consultancy focused on quality, regulatory and technical consulting, ... as Chief Operating Officer. , Before joining ... experience leading R&D teams in all aspects of ... leadership positions at Covidien (Medtronic), Regulatory Compliance Associates ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 What are ... should physicians request references? When are interviews scheduled, how ... employment opportunities?, Both training and practicing physicians who are ... these questions and more at the PracticeLink Physician Career ... The drop-in Job Fair is from 5:30 to 8:30 ...
Breaking Medicine News(10 mins):Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 3Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... David Bereit, director of the nation-wide ... reinvigorated the grassroots pro-life movement, will be ... Jan. 23, 2009.(Logo: http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO )Bereit,s revolutionary ... community outreach touched 204 cities across 49 ...
... changes can make all the difference , , TUESDAY, Dec. ... that continues to sweep across the United States has ... disease, up more than 3 million people since 2005. ... wave of illnesses and disabilities brought on by diabetes ...
... adults and 19 percent of children taking chemotherapy drugs in ... or experienced other mistakes involving their medications, according to a ... of pediatrics at the University of Massachusetts Medical School, and ... Journal of Clinical Oncology . , "As cancer care continues ...
... therapeutic range of utmost importance, study finds , , TUESDAY, ... can be highly effective in preventing strokes and treating ... best way manage the drug therapy. , Boston University ... figured out the optimal dosing levels to help patients, ...
... Resort & Spa,is proud to announce the debut of ... in time for holiday travelers. The resort,s Venus ... the size of the pre-,existing facility to 27,000 sq. ... Club Room, VIP suite, an expansive fitness center,relaxation room ...
... , ... Rosemont, IL (Vocus) December 30, 2008 -- Utilizing an Automated ... at an athletic event can mean the difference between life and death ... a study published in the inaugural edition of Sports Health : ...
Cached Medicine News:Health News:40 Days for Life Leader to Speak at Personhood Conference 2Health News:America Losing the Fight With Type 2 Diabetes 2Health News:America Losing the Fight With Type 2 Diabetes 3Health News:Errors involving medications common in outpatient cancer treatment 2Health News:Optimal Warfarin Dosing Improves Anticoagulation Control 2Health News:CuisinArt Resort & Spa Debuts $10 Million Expansion of World-Class Venus Spa 2Health News:Study Stresses Importance of Availability of Automated External Defibrillators at Athletic Events 2Health News:Study Stresses Importance of Availability of Automated External Defibrillators at Athletic Events 3
... Ultra MD Super Pulse sealed CO2 ... versatility backed by the experience and support ... years of surgical laser experience. All settings ... finger. The Ultra MD Super Pulse surgical ...
The compact size and portability of the Epic system makes it a cost-effective solution for single or multi-office use....
A soft contact lens that lets presbyopes see clearly and comfortably at all distances , without the hassles of bifocals or reading glasses. Recommended for daily wear. Also approved for extended wear...
... display of corneal layers: endothelium, ... epithelial layers. Accurate analysis of ... keratocytes, nerve fibres, basal & ... surgery and pathology: optical pachymetry, ...
Medicine Products: